<DOC>
	<DOCNO>NCT01246999</DOCNO>
	<brief_summary>A total 88 child 2 9 year age randomize receive two dose schedule either license live attenuated trivalent seasonal influenza vaccine ( LAIV ) license inactivated seasonal influenza vaccine ( TIV ) TIV follow LAIV LAIV follow TIV separate 28 day . Children laboratory document history prior H1N1 infection exclude .</brief_summary>
	<brief_title>Effect Age Prior Immunity Response Seasonal Influenza Vaccines Children</brief_title>
	<detailed_description>The study conduct randomize , prospective , open-label evaluation clinical tolerability , vaccine virus shed , serum mucosal antibody response vaccination either live trivalent influenza vaccine ( LAIV ) trivalent influenza vaccine ( TIV ) healthy child age 2 9 year . Children screen antibody A/Brisbane/57/07 ( H1N1 ) A/California/07/09 ( H1N1 ) , A/Perth/16/2009 ( H3N2 ) B/Brisbane/60/2008 indicate time start study . They randomize base antibody level . Children prior document infection 2009 pandemic H1N1 virus exclude . Vaccine administer day 0 28 . Safety vaccination assess use symptom collect parent 7 day dose vaccine . Serum obtain prior day 28 follow dose vaccine assess antibody HAI , ELISA , neutralization technique . Nasal secretion obtain nasal wick prior day 28 dose assess HA-specific IgA ( immune globulin A ) IgG ( immune globulin G ) antibody ELISA . Nasal swabs obtain day 2 , 4 , 7 dose live vaccine assess presence magnitude vaccine virus shed live attenuate vaccine rtRT-PCR ( real-time reverse transcriptase polymerase chain reaction ) TCID50 ( 50 % tissue culture infectious dos ) MDCK ( Madin Darby Canine Kidney ) cell .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 9 year , inclusive . No prior history laboratory document infection novel H1N1 virus The subject must good health , determine : vital sign ( heart rate &lt; 140 bpm ; blood pressure : systolic ≥ 90 mm Hg ≤140 mm Hg ; diastolic ≤ 90 mm Hg ; oral temperature &lt; 100.0ºF ( fahrenheit ) ; medical history ; target physical examination , necessary , base medical history . Stable medical condition define : recent increase prescription medication , dose , frequency medication last 3 month health outcome specific disease consider within acceptable limit last 6 month . The subject/parents able understand comply plan study procedure , include available study visit . The subject/parents provide informed consent prior study procedure . ( An assent obtain child require institutional IRB ( Institutional Review Board . ) Subjects laboratory documented history previous novel H1N1 infection . History egg allergy allergy component vaccine . History wheeze . The subject immunosuppressed result underlie illness treatment immunosuppressive cytotoxic drug , use anticancer chemotherapy radiation therapy . The subject active neoplastic disease . The subject longterm ( great 2 week ) use oral parenteral steroid , highdose inhaled steroid ( &gt; 800 mg/day beclomethasone dipropionate equivalent ) within precede 6 month ( nasal topical steroid allow ) . The subject receive immunoglobulin another blood product within 3 month prior enrollment study . The subject receive inactivated vaccine within 2 week live vaccine within 4 week prior enrollment study plan receive another vaccine within next 28 day ( 56 day vaccine naïve recipient ) . The subject acute chronic medical condition , opinion investigator , would render vaccination unsafe would interfere evaluation response . These condition include chronic condition recognize risk factor influenza complication contraindication live vaccination , include chronic cardiac ( exclusive hypertension ) pulmonary condition ( include asthma ) , diabetes mellitus , renal impairment . The subject acute illness oral temperature great 99.9 degreesF ( 37.7 degree C ) within 3 day prior enrollment vaccination . Subjects acute illness treat symptom resolve eligible enroll long treatment complete symptom resolve &gt; 3 day prior enrollment . The subject currently participate plan participate study involve experimental agent ( vaccine , drug , biologic , device , blood product , medication ) receive experimental agent within 1 month prior enrollment study , expect receive another experimental agent participation study , intend donate blood study period . The subject condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol . The subject know human immunodeficiency virus , hepatitis B , hepatitis C infection . The subject previous history GuillainBarré syndrome within 6 week receipt influenza vaccination . The subject condition principal investigator ( PI ) believe may interfere successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>A/California/7/2009-like ( 2009 H1N1 )</keyword>
	<keyword>A/Perth/16/2009-like ( H3N2 )</keyword>
	<keyword>B/Brisbane/60/2008-like ( B/Victoria lineage )</keyword>
</DOC>